

Beta₂ Adrenergic Agents – Short-Acting Review

12/01/2010

Copyright © 2004 – 2010 by Provider Synergies, L.L.C. All rights reserved.
Printed in the United States of America.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

*Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
10101 Alliance Road, Ste 201
Cincinnati, Ohio 45242*

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCReDitor@magellanhealth.com.



Together, we can do more.

Beta₂ Adrenergic Agents, Short-Acting Review

FDA-Approved Indications

Drug Name	Manufacturer	Reversible Bronchospasm		Prevention of Exercise Induced Broncho-spasm	Chronic Obstructive Pulmonary Disease (COPD)	Age of Use (years)
		Prevention and Treatment	Relief			
Short-Acting Inhalation Agents						
albuterol HFA MDI (Proventil HFA, Ventolin HFA, ProAir HFA) ^{1,2,3}	Proventil HFA [®] Schering	X	X	X		≥4
	Ventolin HFA [®] GlaxoSmithKline					
	ProAir HFA [®] TEVA					
albuterol inhalation	generic		X			infants and older
albuterol low-dose inhalation solution	generic					children 2-12 years and adolescents
levalbuterol inhalation solution (Xopenex [®]) ⁴	generic/Sepracor	X				≥6
levalbuterol HFA MDI (Xopenex [®] HFA) ⁵	Sepracor	X				≥4
metaproterenol inhalation solution ⁶	generic	X	X		X	≥6
pirbuterol MDI (Maxair [®] Autohaler) ⁷	Graceway	X				≥12
Oral Agents						
albuterol oral syrup ⁸	generic		X			≥2
albuterol oral tablets ⁹	generic		X			≥6
metaproterenol oral syrup ¹⁰	generic	X			X	≥6
metaproterenol oral tablets ¹¹	generic	X				≥6
terbutaline tablets ¹²	generic		X		X	≥12

HFA=hydrofluoroalkane; MDI=metered-dose inhaler

Overview

Beta₂-agonist bronchodilators are used for the treatment and prevention of bronchospasm associated with asthma, prophylaxis of exercise-induced bronchospasm (EIB), and in the treatment of chronic obstructive pulmonary disease (COPD).

Asthma

Short-acting beta₂-agonists have not been shown to be as beneficial as controller medications for asthma management, but due to their rapid onset, they are useful for temporary relief of bronchoconstriction and the accompanying acute symptoms such as wheezing, chest tightness, and cough.¹³

The 2007 guidelines from the National Asthma Education and Prevention Panel (NAEPP) of the National Heart Lung and Blood Institute (NHLBI) recommend that for patients over age five years with moderate persistent asthma or asthma not controlled by low-dose corticosteroids that consideration be given for use of a combination of inhaled corticosteroids and long-acting beta₂-agonists or for increasing the dose of inhaled corticosteroids. For patients with severe persistent asthma, a combination of a long-acting beta₂-agonist and an inhaled corticosteroid is recommended. For exercise-induced bronchospasm, long-acting beta₂-agonists may be used for prevention; however, it is noted that frequent or chronic use may disguise poorly controlled persistent asthma.

In November 2007, the NAEPP released a summary of the third report of the Expert Panel (EPR-3) that emphasizes the importance of asthma control and identifies asthma severity as the intrinsic intensity of the disease process. The recommendation from EPR-3 is to assess severity to initiate therapy and assess control to adjust therapy in patients as young as five years of age.

In 2007, the Global Initiative for Asthma (GINA) guidelines for asthma management and prevention were updated to reflect a change in focus from asthma severity to asthma control.¹⁴ Asthma control is defined as no or minimal daytime symptoms; no limitations of activity; no nocturnal symptoms; no or minimal need for rescue medications; normal or near normal lung function; and no exacerbations. A five-step treatment approach is discussed in these guidelines that offer flexibility to step up treatment when asthma is uncontrolled or step down treatment when asthma is controlled. These guidelines suggest treatment with short-acting beta₂-agonists only on an as-needed basis particularly if patients experience only occasional daytime symptoms of short duration. When symptoms are more frequent and/or worsen periodically, patients require regular controller therapy.

In 2008, the GINA guidelines were further updated to produce a more streamlined, user-friendly document that emphasizes the importance of asthma control with appropriate treatment. The asthma classification system is defined as three levels of control: controlled, partly controlled, or uncontrolled. Roles of other medications used to treat asthma (e.g., leukotriene modifiers, long-acting beta-agonists, cromones, and inhaled glucocorticoids) have evolved since prior versions of the guidelines and have been included in the 2008 update.¹⁵

In December 2009, the GINA guidelines were updated to introduce the concept of patients with difficult-to-treat asthma who are relatively insensitive to the effect of corticosteroids and may sometimes be unable to achieve the same level of asthma control as other patients with asthma. Also, increased use of reliever medications is a warning of deterioration in asthma control that indicates a need to reassess treatment.¹⁶

According to the May 2009 Global Initiative for Asthma (GINA) update to the Global Strategy for

the Diagnosis and Management of Asthma in Children five years and younger, rapid-acting inhaled beta-agonists are the most effective bronchodilators available and the preferred reliever treatment for asthma in children five years and younger.¹⁷ A pressurized metered dose inhaler (MDI) with a valved spacer (with or without face mask) is the preferred delivery system. Spacers are designed differently and may have varying doses as a result so it is recommended that a spacer with documented efficacy in young children is used. Nebulizers remain a viable alternative delivery system for use in the small number of children who are not able to be taught effective use of the spacer.

COPD

Bronchodilator medications are central to the symptomatic management of COPD.^{18,19,20,21} They improve emptying of the lungs, tend to reduce dynamic hyperinflation at rest and during exercise, and improve exercise performance.²² They are given either on an as-needed basis for relief of persistent or worsening symptoms or on a regular basis to prevent or reduce symptoms. Regular bronchodilation with these drugs does not modify the decline of function in mild COPD or the prognosis of the disease.²³ The principal bronchodilator treatments are beta₂-agonists, anticholinergics, and theophylline. These may be given either as monotherapy or in combination. While short-acting beta₂-agonists can be used on an as-needed basis in mild COPD, regular treatment with a long acting agent is required as the disease progresses.²⁴

In January 2008, the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines were released and state that beta₂-agonist bronchodilators are among the principal treatments for symptomatic management of COPD.²⁵ The guidelines state that patient care should be based on level of disease severity and clinical symptoms. The following medications are identified based on the likely order of introduction in treatment: short-acting bronchodilators to be used as needed, may add regular treatment with long-acting bronchodilators including one or more of the following: long-acting beta₂-agonists, long-acting anticholinergics, combination short-acting beta₂-agonist plus anticholinergic in one inhaler, and/or methylxanthines. For patients with repeated exacerbations, inhaled corticosteroids may be added to the daily treatment regimen. The guidelines also state that regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators.

In December 2009, the update to the GOLD guidelines continues to support the aforementioned premise that regular treatment with long-acting bronchodilators remains more effective and convenient than treatment with short-acting bronchodilators. This 2009 update also reflects four stages of spirometric classification of COPD severity instead of five: Stage One – Mild; Stage Two – Moderate; Stage Three – Severe; and Stage Four – Very Severe. None of the existing medications for COPD have been shown to modify the long-term decline in lung function that is the hallmark of this disease. Therefore, pharmacotherapy for COPD is used to decrease symptoms and/or complications.²⁶

In 2005, the American College of Chest Physicians (ACCP) and the American College of Allergy, Asthma, and Immunology (ACAAI) issued joint evidence-based guidelines for selecting aerosol delivery devices for use in asthma or COPD.²⁷ The authors performed a systematic review of randomized controlled trials comparing the efficacy and adverse effects of treatment using nebulizers versus pressurized MDIs with or without a spacer/holding chamber versus DPIs as delivery systems for beta₂-agonists, anticholinergic agents, and corticosteroids in several commonly encountered clinical settings and patient populations. The authors conclude that devices used for the delivery of bronchodilators and steroids can be equally efficacious.

Pharmacology

Beta-agonists stimulate adenyl cyclase, the enzyme that catalyzes the formation of cyclic-3'5' adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity, especially from mast cells. Beta₂-agonists relieve reversible bronchospasm by relaxing the smooth muscles of the bronchioles in conditions associated with asthma, COPD, or bronchiectasis. Bronchodilation may additionally facilitate expectoration.

Although there are both beta₁ and beta₂ receptors in the heart, the latter are more predominant in the lungs, where they serve as the primary adrenergic receptors in bronchial smooth muscle. In order to reduce cardiac toxicities (e.g., tachyarrhythmias), the use of beta₂ specific agonists is preferred in the treatment of bronchospasm. This has minimized the use of less specific and less safe agents such as epinephrine (Primatene Mist[®]) and isoproterenol (Isuprel[®]). To further reduce cardiac toxicities, non-systemic dosage forms given by inhalation are preferred to oral dosage forms.

Since the signing of the Montreal Protocol in 1987, new propellants, such as hydrofluoroalkane (HFA), for use in pressurized metered-dose inhalers that are non-ozone-depleting have been developed. Several randomized, double-blind, placebo-controlled, crossover studies have shown that albuterol MDI pressurized by HFA are equivalent, in terms of efficacy and tolerability, to the original chlorofluorocarbon (CFC) albuterol MDI in both adolescents and adults.^{28,29,30,31} This equivalence was shown for both the treatment and prophylactic (EIB) indications of albuterol. The FDA completed its phase-out of albuterol inhalers using ozone-depleting CFCs as propellants on December 31, 2008. Patients who used albuterol inhalers containing CFCs were switched to alternative inhalers that contain a propellant called hydrofluoroalkane (HFA).

On April 13, 2010, the FDA announced that in accordance with the longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and COPD will be gradually removed from the U.S. marketplace.³² These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which act as propellants to move medication out of the inhaler and into the lungs of patients. Alternative medications that do not contain CFCs are available. Patients using the inhalers scheduled to be phased out should talk to their health care professional about switching to one of several alternative treatments currently available. Until then, patients should continue using their current inhaler medication. Short-acting beta-agonists impacted by this announcement are metaproterenol inhaler (Alupent) and pirbuterol (Maxair Autohaler). The last date that Alupent inhaler is to be manufactured, sold, or dispensed in the United States is June 14, 2010. The last date that Maxair Autohaler is to be manufactured, sold, or dispensed in the United States is December 31, 2013.

Pharmacokinetics

Drug	Relative β_2 Specificity	Onset of Action (minutes)	Duration of Action (hours)
Short-Acting Inhalation Agents			
albuterol HFA MDI (ProAir HFA, Proventil HFA, Ventolin HFA) ^{33,34,35}	$\beta_2 \gg \beta_1$	5.4-8.2	3-6
albuterol inhalation solution (generic, Accuneb) ^{36,37}	$\beta_2 \gg \beta_1$	5-15	3-6
levalbuterol inhalation solution (Xopenex) ³⁸	$\beta_2 \gg \beta_1$	10-17	5-8
levalbuterol HFA MDI (Xopenex HFA) ³⁹	$\beta_2 \gg \beta_1$	5-10	3-6
metaproterenol inhalation solution ⁴⁰	$\beta_2 > \beta_1$	5-30	2-6
pirbuterol MDI (Maxair) ⁴¹	$\beta_2 > \beta_1$	≤ 5	5
Oral Agents			
albuterol syrup, tablets ^{42,43}	$\beta_2 \gg \beta_1$	30	4-8
metaproterenol syrup, tablets ⁴⁴	$\beta_2 > \beta_1$	30	≥ 4
terbutaline tablet ⁴⁵	$\beta_2 \gg \beta_1$	30	4-8

Contraindications/Warnings^{46,47,48,49,50,51,52,53,54}

No specific contraindications exist for the short-acting beta-agonists.

Warnings that are common to the short-acting beta-agonists include: paradoxical bronchospasm (can be life threatening), cardiovascular effects (e.g., effects on blood pressure and pulse rate), excessive dose and usage, acute deterioration of asthma and use of anti-inflammatory agents (e.g. corticosteroids). Short-acting beta-agonists should be used with caution in patients with heart disease, seizure disorder, diabetes, and hyperthyroidism.

There have been rare reports of seizures in patients receiving terbutaline; seizures did not recur in these patients after the drug was discontinued.

Drug Interactions^{55,56,57,58,59,60,61,62,63,64}**Monoamine Oxidase (MAO) Inhibitors and Tricyclic Antidepressants**

All beta₂-agonists should be administered with extreme caution to patients being treated with MAO inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because these agents may potentiate the action of adrenergic agonists on the cardiovascular system. Allow two weeks after discontinuation of MAO inhibitors before initiating therapy with agents in this category.

Beta-Adrenergic Receptor Blocking Agents

Beta-blockers not only block the pulmonary effect of beta-agonists but may also produce severe bronchospasm in patients with asthma or COPD. Therefore, patients with asthma or COPD should not normally be treated with beta-blockers. However, under certain circumstances, such as prevention of myocardial re-infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma or COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

Diuretics

ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non-potassium-sparing diuretics. Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.

Digoxin

Mean decreases of 16 and 22 percent in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of racemic albuterol, respectively, to normal volunteers who had received digoxin for ten days. The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear; nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol and levalbuterol.

Adverse Effects

Drug	Headache	Nausea/ Vomiting	Nervousness	Palpitations	Tachycardia	Tremor
Short-Acting Inhalation Agents						
albuterol HFA MDI (Proventil HFA, Ventolin HFA, ProAir HFA) ^{65,66,67}	7-20	7 - 10	7	<3	<3 - 7	2-7
albuterol inhalation solution (generic, Accuneb) ^{68,69}	nr	1.7/0.9	reported	reported	nr	reported
levalbuterol inhalation solution (Xopenex) ⁷⁰	7.6 - 11.9	<2	2.8 - 9.6	reported	2.7 - 2.8	0 - 6.8
levalbuterol HFA MDI (Xopenex HFA) ⁷¹	reported	10.5	reported	reported	reported	reported
metaproterenol inhalation solution ⁷²	3.3	7.7 - 14	14.1	<1	2.5 – 16.6	2.5 – 33
pirbuterol MDI (Maxair) ⁷³	1.3	1.3	4.5	1.3	1.3	1.3
Oral Agents						
albuterol syrup ⁷⁴	4	<1 - 2	9 - 15	<1	1 - 2	10
albuterol tablets ⁷⁵	7	2	20	5	5	20
metaproterenol syrup ⁷⁶	1.1	1.3	4.8	<1	6.1	1.6
metaproterenol tablets ⁷⁷	7	0.8 - 3.6	20.2	3.8	17.1	16.9
terbutaline tablets ⁷⁸	7.8 - 10	1.3 - 10	<5 - 31	≤23	1.3 - 3	<5 – 38

Adverse effects data are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all-inclusive. nr = not reported.

Special Populations^{79,80,81,82,83,84,85,86,87}**Pediatrics**

Most of the short-acting beta-agonists have been studied in pediatric patients and shown to be safe and effective in children as young as two years of age. Important to note is that the safety and effectiveness of pirbuterol (Maxair) in children has not been established in children under 12 years of age. There is insufficient clinical data to establish safety and efficacy of terbutaline sulfate; therefore, it is not recommended for patients under the age of 12 years.

Pregnancy

There are no adequate and well-controlled studies of these agents in pregnant women. Terbutaline is Pregnancy Category B. All of the short-acting beta-agonists are Pregnancy Category C. They should only be used during pregnancy if the potential benefit justifies the potential risk.

Other considerations – renal, hepatic, race, etc.

These agents have not been studied in a geriatric population. Special caution should be observed when using these agents in elderly patients with coexisting conditions like impaired renal function and cardiovascular disease that could be adversely affected by this class of drug.

No dosage adjustments are needed in the hepatically impaired patients who use albuterol, albuterol HFA, pirbuterol, and levalbuterol.

Exercise caution and monitor patients with renal impairment who use albuterol, albuterol HFA, pirbuterol, levalbuterol. No special monitoring or dosage adjustments are needed in patients with renal impairment who use metaproterenol.

Dosages

Drug	Usual Adult Dosage	Usual Pediatric Dose	Availability
Short-Acting Inhalation Agents			
albuterol HFA MDI (Proventil HFA, Ventolin HFA, ProAir HFA) ^{88,89,90}	2 inhalations every 4-6 hrs as needed Prevention of EIB: 2 inhalations 15-30 minutes prior to exercise	2 inhalations every 4-6 hrs as needed Prevention of EIB: 2 inhalations 15-30 minutes prior to exercise	90 mcg per actuation
albuterol inhalation solution (generic, Accuneb) ^{91,92}	2.5 mg every 6-8 hrs as needed	0.63-2.5 mg three to four times daily as needed	generic: 2.5 mg/3 mL, 5 mg/mL Accuneb or low-dose generic: 0.63 mg/3 mL, 1.25 mg/3 mL
levalbuterol inhalation solution (Xopenex) ⁹³	0.63-1.25 mg three times daily	0.31-0.63 mg three times daily	0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL
levalbuterol HFA MDI (Xopenex HFA) ⁹⁴	2 inhalations every 4-6 hrs as needed	2 inhalations every 4-6 hrs as needed	45 mcg per actuation
metaproterenol inhalation solution ⁹⁵	10-15 mg three to four times daily	5-10 mg three to four times daily	8 mg/2 mL, 5 mg/mL, 12 mg/2 mL,
pirbuterol MDI (Maxair) ⁹⁶	2 inhalations every 4-6 hrs. Not to exceed 12 inhalations per day.	--	200 mcg per actuation
Oral Agents			
albuterol oral syrup ⁹⁷	2-4 mg every 6-8 hrs	0.1-0.2 mg/kg every 8 hrs	2 mg/5 mL
albuterol oral tablets ⁹⁸	2-4 mg every 6-8 hrs	2 mg every 6-8 hrs	2 mg, 4 mg
metaproterenol oral syrup ⁹⁹	20 mg three to four times daily	10 mg three to four times daily	10 mg/5 mL
metaproterenol oral tablets ¹⁰⁰	20 mg three to four times daily	Age 6 – 9 years old or weight < 60lbs: 10 mg three to four times daily Age > 9 years old or weight > 60lbs: 20 mg three to four times daily	10 mg, 20 mg
terbutaline tablets ¹⁰¹	2.5-5 mg three times daily	2.5 mg three times daily	2.5 mg, 5 mg

Clinical Trials

Search Strategy

Articles were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this class. Randomized, controlled, comparative trials are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance.

ASTHMA

albuterol inhalation solution (Proventil, Ventolin) versus levalbuterol inhalation solution (Xopenex)

In a randomized, double-blind, placebo-controlled, crossover study, 20 adults with mild-to-moderate asthma received single doses of levalbuterol inhalation solution (0.31, 0.63, and 1.25 mg) and albuterol inhalation solution (2.5 mg).¹⁰² All doses of active treatment produced a significantly greater degree of bronchodilation (measured by change in FEV₁) than placebo, and there were no significant differences between any of the active treatment arms. The bronchodilator response of levalbuterol 1.25 mg and albuterol 2.5 mg showed similar efficacy over the six hour evaluation period, except for a slightly longer duration of action after administration of levalbuterol 1.25 mg. Systemic beta adrenergic adverse effects were observed with all active doses. Levalbuterol 1.25 mg produced a slightly higher rate of systemic beta adrenergic adverse effects than the albuterol 2.5 mg dose. This study was funded by the manufacturer of levalbuterol.

A multicenter, randomized, double-blind, placebo- and active-controlled study was conducted in 338 children with mild-to-moderate asthma.¹⁰³ Following a one-week placebo run-in period, subjects were randomized to nebulized levalbuterol 0.31 or 0.63 mg, albuterol 1.25 or 2.5 mg, or placebo given three times daily for three weeks. Of the 338 patients who were randomized, 316 patients completed the study. Efficacy, measured by mean peak change in FEV₁, was demonstrated for all active treatment regimens compared with placebo. The onset and duration of effect of levalbuterol are consistent with those of albuterol.

A randomized, double-blind, controlled trial was conducted in children age one to 18 years (n=482) in the emergency department (ED) and inpatient asthma care unit of an urban tertiary children's hospital.¹⁰⁴ Patients received a nebulized solution of either 2.5 mg racemic albuterol or 1.25 mg levalbuterol every 20 minutes (maximum six doses). Patients admitted to the asthma care unit were treated in a standardized fashion by using the same blinded drug assigned in the ED. Hospitalization rate was the primary outcome. Hospitalization rate was significantly lower in the levalbuterol group (36 percent) than in the racemic albuterol group (45 percent, p=0.02). The adjusted relative risk of admission in the racemic group compared with

the levalbuterol group was 1.25 (95% confidence interval (CI), 1.01 - 1.57). Hospital length of stay was not significantly shorter in the levalbuterol group (levalbuterol, 44.9 hours; racemic albuterol, 50.3 hours; p=0.63). No significant adverse events occurred in either group.

COPD

albuterol MDI (Proventil, Ventolin) versus formoterol DPI (Foradil) versus salmeterol DPI (Serevent) in COPD

A cross-over, randomized, double-blind, placebo-controlled study was carried out on 20 patients with COPD.¹⁰⁵ Patients underwent pulmonary function testing and dyspnea evaluation in basal condition and at five, 15, 30, 60, and 120 minutes after bronchodilator (albuterol MDI, formoterol DPI, or salmeterol DPI) or placebo administration. The results indicated that in COPD patients with decreased baseline inspiratory capacity, there was a much greater increase of inspiratory capacity after bronchodilator administration, which correlated closely with the improvement of dyspnea sensation at rest. On average, formoterol DPI elicited the greatest increase in inspiratory capacity than the other bronchodilators used.

Meta Analyses

A systematic review of pertinent randomized, controlled, clinical trials was undertaken using MEDLINE, EmBase, and the Cochrane Library databases to determine if a difference in efficacy and adverse effects exists among the various aerosol delivery devices (MDI versus DPI versus nebulizers) used in the management of asthma and COPD exacerbations.¹⁰⁶ A total of 254 outcomes were tabulated. Of the 131 studies that met the eligibility criteria, only 59 (primarily those that tested beta₂-agonists) proved to have useable data. None of the pooled meta-analyses showed a significant difference among devices in any efficacy outcome in any patient group for each of the clinical settings that were investigated. The adverse effects that were reported were minimal and were related to the increased drug dose that was delivered. Each of the delivery devices provided similar outcomes in patients using the correct technique for inhalation.

Summary

Due to its rapid onset of action, relative lack of adverse systemic effects, and availability of multiple dosage forms, albuterol remains the most commonly used short-acting beta₂-agonist bronchodilator. Albuterol CFC MDIs are no longer available as of December 31, 2008. Schering (Proventil HFA), Ivax (ProAir HFA) and GlaxoSmithKline (Ventolin HFA) produce albuterol inhalers using HFA propellant.

In general, oral dosage forms of albuterol are less utilized than the inhaled forms due to systemic beta-adrenergic stimulation of the former, especially in patients sensitive to these effects, such as those with cardiovascular disease. Metaproterenol is neither as beta₂ selective nor as long acting as albuterol, therefore should not be considered for first-line therapy. Another beta₂-agonist, terbutaline, is more beta₂ selective than metaproterenol but is available only as oral tablets. The short duration of action of terbutaline reduces its value in the treatment of bronchoconstriction.

Levalbuterol (Xopenex) is the R-enantiomer form of albuterol. Levalbuterol (Xopenex) inhalation solution has similar efficacy to albuterol inhalation solution when given in equivalent doses. In addition, an HFA-propelled inhaler containing the enantiomer of albuterol is available

as levalbuterol HFA (Xopenex HFA). There are no significant differences in adverse effects between albuterol and levalbuterol formulations.

References

- ¹ Proventil HFA [package insert]. Kenilworth, NJ; Key Pharmaceuticals; September 2009.
- ² Ventolin HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; April 2008.
- ³ ProAir HFA [package insert]. Miami, FL; Ivax; August 2010.
- ⁴ Xopenex [package insert]. Marlborough, NH; Sepracor Inc; August 2007.
- ⁵ Xopenex HFA [package insert]. Marlborough, NH; Sepracor Inc. February 2008.
- ⁶ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁷ Maxair [package insert]. Northridge, CA; 3M Pharmaceuticals; January 2008.
- ⁸ Proventil Syrup [package insert]. Kenilworth, NJ; Schering Corporation; June 1997.
- ⁹ Proventil Repetabs [package insert]. Kenilworth, NJ; Schering Corporation; October 2000.
- ¹⁰ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ¹¹ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ¹² Terbutaline [package insert]. Philadelphia, PA; Global Pharmaceuticals; June 2001.
- ¹³ National Asthma Education and Prevention Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 3. Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthqdln.htm>. Accessed December 3, 2010.
- ¹⁴ Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available at: <http://www.ginasthma.com/GuidelinesResources.asp?l1=2&l2=0>. Accessed December 3, 2010.
- ¹⁵ Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2008. Available at: <http://www.ginasthma.com/Guidelineitem.asp?l1=2&l2=1&intlId=60>. Accessed December 3, 2010.
- ¹⁶ Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2009. Available at: <http://www.ginasthma.com/Guidelineitem.asp?l1=2&l2=1&intlId=1561>. Accessed December 3, 2010.
- ¹⁷ Global Strategy for the Diagnosis and Management of Asthma in Children Five Years and Younger. Global Initiative for Asthma (GINA) 2009. Available at: <http://www.ginasthma.com/Guidelineitem.asp?l1=2&l2=1&intlId=1689>. Accessed December 3, 2010.
- ¹⁸ Vathenen AS, Britton JR, Ebdon P, et al. High-dose inhaled albuterol in severe chronic airflow limitation. *Am Rev Respir Dis*. 1988; 138:850-855.
- ¹⁹ Gross NJ, Petty TL, Friedman M, et al. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. *Am Rev Respir Dis*. 1989; 139:1188-1191.
- ²⁰ Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. *BMJ*. 1988; 297:1506-1510.
- ²¹ Higgins BG, Powell RM, Cooper S, et al. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. *Eur Respir J*. 1991; 4:415-420.
- ²² Wilson DH, Wakefield MA, Steven ID, et al. "Sick of smoking": evaluation of a targeted minimal smoking cessation intervention in general practice. *Med J Aust*. 1990; 152:518-521.
- ²³ The GOLD Guidelines: Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD. Available at: <http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intlId=996>. Accessed December 3, 2010.
- ²⁴ The GOLD Guidelines: Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD. Available at: <http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intlId=996>. Accessed December 3, 2010.
- ²⁵ The GOLD Guidelines. Available at: <http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intlId=996>. Accessed December 3, 2010.
- ²⁶ The GOLD Guidelines: Available at: <http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intlId=2180>. Accessed December 3, 2010.
- ²⁷ Dolovich MB, Ahrens RC, Hess DR, et al. Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest*. 2005; 127:335-371.
- ²⁸ Lumry W, Noveck R, Weinstein S, et al. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. *Ann Allergy Asthma Immunol*. 2001; 86:297-303.
- ²⁹ Langley SJ, Sykes AP, Batty EP, et al. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. *Ann Allergy Asthma Immunol*. 2002; 88:488-93.
- ³⁰ Shapiro G, Bronsky E, Murray A, et al. Clinical Comparability of Ventolin Formulated With Hydrofluoroalkane or Conventional Chlorofluorocarbon Propellants in Children With Asthma. *Arch Pediatr Adolesc Med*. 2000; 154:1219-1225.
- ³¹ Hawksworth RJ, Sykes AP, Faris M, et al. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. *Ann Allergy Asthma Immunol*. 2002; 88:473-7.
- ³² Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm208302.htm>. Accessed December 3, 2010.
- ³³ Ventolin HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; April 2008.
- ³⁴ ProAir HFA [package insert]. Miami, FL; Ivax; August 2010.
- ³⁵ Proventil HFA [package insert]. Kenilworth, NJ; Key Pharmaceuticals; September 2009.
- ³⁶ Proventil Inhalation Solution [package insert]. Kenilworth, NJ; Schering Corporation; February 2002.
- ³⁷ AccuNeb [package insert]. Napa, CA; Dey L.P.; January 2007.
- ³⁸ Xopenex [package insert]. Marlborough, MA; Sepracor; June 2005.
- ³⁹ Xopenex HFA [package insert]. Marlborough, NH; Sepracor Inc. September 2005.
- ⁴⁰ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁴¹ Maxair [package insert]. Northridge, CA; 3M Pharmaceuticals; January 2008.
- ⁴² Proventil Repetabs [package insert]. Kenilworth, NJ; Schering Corporation; October 2000.

- ⁴³ Proventil Syrup [package insert]. Kenilworth, NJ; Schering Corporation; June 1997.
- ⁴⁴ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁴⁵ Terbutaline [package insert]. Philadelphia, PA; Global Pharmaceuticals; June 2001.
- ⁴⁶ Ventolin HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; April 2008.
- ⁴⁷ ProAir HFA [package insert]. Miami, FL; Ivax; August 2010.
- ⁴⁸ Proventil HFA [package insert]. Kenilworth, NJ; Key Pharmaceuticals; September 2009.
- ⁴⁹ Proventil Inhalation Solution [package insert]. Kenilworth, NJ; Schering Corporation; February 2002.
- ⁵⁰ AccuNeb [package insert]. Napa, CA; Dey L.P.; January 2007.
- ⁵¹ Xopenex [package insert]. Marlborough, NH; Sepracor Inc; August 2007.
- ⁵² Xopenex HFA [package insert]. Marlborough, NH; Sepracor Inc. September 2005.
- ⁵³ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁵⁴ Maxair [package insert]. Northridge, CA; 3M Pharmaceuticals; January 2008.
- ⁵⁵ Ventolin HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; April 2008.
- ⁵⁶ ProAir HFA [package insert]. Miami, FL; Ivax; August 2010.
- ⁵⁷ Proventil HFA [package insert]. Kenilworth, NJ; Key Pharmaceuticals; September 2009.
- ⁵⁸ Proventil Inhalation Solution [package insert]. Kenilworth, NJ; Schering Corporation; February 2002.
- ⁵⁹ AccuNeb [package insert]. Napa, CA; Dey L.P.; January 2007.
- ⁶⁰ Xopenex [package insert]. Marlborough, NH; Sepracor Inc; August 2007.
- ⁶¹ Xopenex HFA [package insert]. Marlborough, NH; Sepracor Inc. September 2005.
- ⁶² Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁶³ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁶⁴ Maxair [package insert]. Northridge, CA; 3M Pharmaceuticals; January 2008.
- ⁶⁵ Ventolin HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; April 2008.
- ⁶⁶ ProAir HFA [package insert]. Miami, FL; Ivax; August 2010.
- ⁶⁷ Proventil HFA [package insert]. Kenilworth, NJ; Key Pharmaceuticals; September 2009.
- ⁶⁸ Proventil Inhalation Solution [package insert]. Kenilworth, NJ; Schering Corporation; February 2002.
- ⁶⁹ AccuNeb [package insert]. Napa, CA; Dey L.P.; January 2007.
- ⁷⁰ Xopenex [package insert]. Marlborough, NH; Sepracor Inc; August 2007.
- ⁷¹ Xopenex HFA [package insert]. Marlborough, NH; Sepracor Inc. September 2005.
- ⁷² Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁷³ Maxair [package insert]. Northridge, CA; 3M Pharmaceuticals; January 2008.
- ⁷⁴ Proventil Syrup [package insert]. Kenilworth, NJ; Schering Corporation; June 1997.
- ⁷⁵ Proventil Repetabs [package insert]. Kenilworth, NJ; Schering Corporation; October 2000.
- ⁷⁶ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁷⁷ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁷⁸ Terbutaline [package insert]. Philadelphia, PA; Global Pharmaceuticals; June 2001.
- ⁷⁹ Ventolin HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; April 2008.
- ⁸⁰ ProAir HFA [package insert]. Miami, FL; Ivax; August 2010.
- ⁸¹ Proventil HFA [package insert]. Kenilworth, NJ; Key Pharmaceuticals; September 2009.
- ⁸² Proventil Inhalation Solution [package insert]. Kenilworth, NJ; Schering Corporation; February 2002.
- ⁸³ AccuNeb [package insert]. Napa, CA; Dey L.P.; January 2007.
- ⁸⁴ Xopenex [package insert]. Marlborough, NH; Sepracor Inc; August 2007.
- ⁸⁵ Xopenex HFA [package insert]. Marlborough, NH; Sepracor Inc. September 2005.
- ⁸⁶ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ⁸⁷ Maxair [package insert]. Northridge, CA; 3M Pharmaceuticals; January 2008.
- ⁸⁸ Ventolin HFA [package insert]. Research Triangle Park, NC; GlaxoSmithKline; April 2008.
- ⁸⁹ ProAir HFA [package insert]. Miami, FL; Ivax; August 2010.
- ⁹⁰ Proventil HFA [package insert]. Kenilworth, NJ; Key Pharmaceuticals; September 2009.
- ⁹¹ Proventil Inhalation Solution [package insert]. Kenilworth, NJ; Schering Corporation; February 2002.
- ⁹² AccuNeb [package insert]. Napa, CA; Dey L.P.; January 2007.
- ⁹³ Xopenex [package insert]. Marlborough, MA; Sepracor; August 2007.
- ⁹⁴ Xopenex HFA [package insert]. Marlborough, NH; Sepracor Inc. September 2005.
- ⁹⁵ Metaproterenol [package insert]. Arm-a-Med; November 1994.
- ⁹⁶ Maxair [package insert]. Northridge, CA; 3M Pharmaceuticals; July 2003.
- ⁹⁷ Proventil Syrup [package insert]. Kenilworth, NJ; Schering Corporation; June 1997.
- ⁹⁸ Proventil Repetabs [package insert]. Kenilworth, NJ; Schering Corporation; October 2000.
- ⁹⁹ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ¹⁰⁰ Alupent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; July 2001.
- ¹⁰¹ Terbutaline [package insert]. Philadelphia, PA; Global Pharmaceuticals; June 2001.
- ¹⁰² Handley DA, Tinkelman D, Noonan M, et al. Dose-response evaluation of levalbuterol verses racemic albuterol in patients with asthma. *J Asthma*. 2000; 37:319-27.
- ¹⁰³ Milgrom H, Skoner DP, Bensch G, et al. Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol. *J Allergy Clin Immunol*. 2001; 108:938-45.
- ¹⁰⁴ Carl JC, Myers TR, Kirchner HL, et al. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. *J Pediatr*. 2003; 143(6):731-6.
- ¹⁰⁵ Di Marco F, Millic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. *Eur Respir J*. 2003; 21:86-94.

¹⁰⁶ Dolovich MB, Ahrens RC, Hess DR, et al. Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest*. 2005; 127:335-371.